Trials / Completed
CompletedNCT00420381
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose is to assess the efficacy and toxicity of the study agent, enzastaurin, in participants with recurrent or persistent ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | enzastaurin | 1125 mg loading dose then 500 mg, oral, daily, until progressive disease |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2008-05-01
- Completion
- 2014-12-01
- First posted
- 2007-01-11
- Last updated
- 2020-12-19
- Results posted
- 2020-12-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00420381. Inclusion in this directory is not an endorsement.